Designed to FAIL: Vanderbilt University's role in the Plandemic
Designed to FAIL: Vanderbilt University's role in the Plandemic
The same Institution that developed Remdesivir along with the NIH sabotaged their competition- Hydroxychloroquine.
INTRODUCTION: Thanks to FOIA request of Judicial Watch, a picture of the criminal conspiracy of the NIH and the FDA of the United States to block safe and effective “early treatments” of COVID-19 is becoming clear. In the winter and early spring of 2020, plans were made to distribute hydroxychloroquine (HCQ), one of several safe and effective zinc ionophores, from a national stockpile to the public The goal was to have a safe and effective rna virus killer in the hands of the public that we could use at the first onset of symptoms. It would also have served as a preventative measure. The Pandemic never would have happened.
Various members of government, most notably Anthony Fauci and Janet Woodcock, sabotaged this plan. They negotiated a plan, perhaps with President Trump, to not distribute the zinc ionophore to the public under an Investigational New Drug (IND) authorization, as was the original plan. Instead, they created and negotiated a plan to allow HCQ to be used in hospital settings only under an Emergency Use Authorization (EUA). This plan intentionally allowed the SARS-CoV-2 virus to spread in the public. The zinc ionophores, that the conspirators blocked, would have killed the virus by interrupting its ability to replicate, and stopped the spread of the virus. Their medical qualifications suggest that they had to know this, despite their objections that their was no clinical trial proof.
Fauci et al's plan intentionally allowed the virus to advance to stages of disease in people to an extent that they required hospitalization. The plan sadistically allowed the use of HCQ in hospitals for people who were on their death beds only.
But even these unforgivable sins were not did not go far enough for them. They set out to destroy the narrative that HCQ, and grant an EUA for an unsafe and ineffective treatment of an NIH-funded pharma product, Remdesivir.
They funded flawed clinical trials of HCQ, "designed to fail," at Vanderbilt University. Vanderbilt University was the lead University that had created Remdesivir.
The rest of this article combines relevant facts establishing what I have laid out in the Introduction. It combines several main sources. 1. Transcript of Dr. Zev Zelenko discussing HCQ. 2. Article written by Dr. Steven Hatfill, a member of COVID-19 Task Force. 3. Whistleblower complaint of Rick Bright. 4. FOIA request related to HCQ by Judicial Watch. 5. Press releases by the FDA and NIH. 6. Public comments made by Anthony Fauci and President Trump on HCQ. 7. Articles from Vanderbilt and North Carolina universities discussing the development of Remdesivir.
Those sources are combined in a timeline format. In some places I make relevant observations to prove the points that I made in the Introduction. A section on the development of Remdesivir will be included after the timeline.
TIMELINE BEGINS BELOW
1.21.20. The US announced its first official case of COVID-19 on 21 January, 2020.
1.29.20. The US COVID-19 Task Force was formed on January 29, 2020. Alex Azar, Secretary of Health and Human Services, told President Trump that the United States had a very good response to COVID-19 in mind. He said that everything "was under control." This screenshot is from Rick Bright's Whistleblower Complaint.
On February 3, 2020, Dr. Steven Hatfill begins advising President Trump on the COVID-19 response. Later he would write "How a Single Point Failure Destroyed the National Pandemic Plan." Hatfill's article is also a timeline of relevant facts that I am referencing here. Please click on his link. I hope he doesn't mind if I cut and paste some of his observations for the reader's convenience. "I watched in disbelief as a small number of senior federal employees defied orders and their oaths ... to systematically ignore and destroy a validated National Pandemic Response Plan..."
On February 25, 2020, a NIH clinical trial of Remdesivir to treat COVID-19 began. "Participants in the NIH-sponsored trial must have laboratory-confirmed SARS-CoV-2 infection and evidence of lung involvement, including rattling sounds when breathing (rales) with a need for supplemental oxygen or abnormal chest X-rays, or illness requiring mechanical ventilation. Individuals with confirmed infection who have mild, cold-like symptoms or no apparent symptoms will not be included in the study."
It is important to note here that the NIH did not even bother to test if Remdesivir would work in early stages. Remdesivir was only a late-stage treatment option by design. The NIH excluded people from the test who had "mild, cold-like symptoms." This is more evidence that the NIH response to the Pandemic was to intentionally allow the virus to spread. There also would have been no need for a late-stage treatment of the NIH-developed Remdesivir if HCQ had stopped the virus in the early stages.
By March, 2020, members of of the US COVID-19 Task Force had 10 peer-reviewed studies and seven observational reports that, according to Dr. Steven Hatfill, showed no concerns over adverse cardiac effects. It is important to note that many studies showed no concerns over cardiac events with HCQ. The FDA would take issue with that later. The clinical trials with HCQ that were awarded to Vanderbilt in April used azithromycin, a product known to cause cardiac events. It was an effort on their part to create a false association of cardiac events and HCQ, when azithromycin was known to be a product that caused cardiac events. Screenshot is from Dr. Steven Hatfill.
March 6, 2020. This is one of the videos from "Medcram" that Dr. Zev Zelenko mentioned influenced his development of HCQ/Zinc treatment protocol. "Coronavirus Epidemic Update 32: Important Data from South Korea, Can Zinc Help Prevent COVID-19?" I am including this video for a few reasons. One, it is an excellent explanation that Dr. Seheult deserves credit for. It helped me understand how zinc ionophores worked. Two, it establishes that it was very well-known by March 6, 2020 that Zinc was the actual chemical that stopped the Sars-CoV-2 virus from replicating, and that the study awarded to Vanderbilt that used HCQ and azithromycin did not use sound medical theory. Three, this video was mentioned by Dr. Zev Zelenko, who said it was influential to him. Dr. Zelenko's comments on this video and on his development of HCQ protocols are included below the video.
Here's a transcript I made of what Dr. Zelenko later said about how he developed his HCQ/Zinc protocol:
I started thinking outside of the box. I looked at Episode 34 of MedCram on youtube where the Professor there explains the role of Zinc ionophore which ? and how they work. How zinc inhibits rna-dependent rna preliminaries. And rna-dependent rna preliminaries turns out to be the essential enzyme involved in rna viral replication. All the strains of COVID, all the strains of influenza, and it turns out rnsv? as well. Then I looked how South Korea (MedCram March 6, 2020) had treated these patients. And they used hydroxychloraquine and Zinc in hospitalized patients, with some minor success. Then I looked how Dr. Didier Raoult of Marseille, France (12:23) was treating patients. (Preliminary results March 17, 2020) (Results published May 5, 2020). He was using hydroxychloroquine and azithromycin, no zinc, with some success. So I said to myself, "you know what, why don't I take all the available evidence, put it together, tweak the dosing to reflect less severe patients, and administer it, and let's see what happens. The second I started using this approach, people stopped going to the hospital. Now, by the way, I don't have to convince you, now. There are dozens of studies that corroborate what I'm saying. I'm not going back 18 months to prove something that's already been proven. OK. So, and I did publish my data. With two world-class scientists, in a peer-reviewed journal which has now been quoted 200 times as the basis of all the research. ... And by the way, that was not a study. That was a report of real-world evidence. There was no clinical design to this. This was just a simple doctor practicing simple medicine.
On March 18, 2020, Donald Trump had a press conference. He invoked the "Defense Production Act" in response to the COVID-19 Pandemic. "We're going to defeat the invisible enemy. I think we're going to do it even faster than we thought. And it will be a complete victory. It will be a total victory."
On March 19, 2020, a reporter asked Anthony Fauci if there is any evidence to suggest that HCQ could be a prophylaxis against COVID-19. ABC. Anthony Fauci: "The answer is no. And the evidence you're talking about John is anecdotal evidence. So as the Commissioner of FDA and the President mentioned yesterday, we're trying to strike a balance between making something to make something with a potential of an effect to the American people available at the same time that we do it under the auspices of a protocol that would give us information to determine if its truly safe and truly effective. But the information that you're referring to specifically is anecdotal. It was not done in a controlled clinical trial."
On March 21, 2020, President Trump tweeted about Hydroxychloroquine and Azithromycin. The President did not mention Zinc, a necessary counterpart to the zinc ionophore HCQ. The Hydroxychloroquine/Azithromycin combination was later reported on May 1 to be a combination that caused cardiac problems. It calls into serious question the intentions or medical credentials of whoever designed this study (unknown to me at this time). The HCQ/AZM combination is both far less likely to be effective and more likely to cause cardiac adverse events than the HCQ/Zinc combination.
On March 23, 2020,Secretary of Health and Human Services Alex Azar directs Rick Bright to establish an Investigational New Drug (IND) authorization of HCQ. It is important to note that the directive of Azar specifically stated that the authorization of HCQ should allow use outside of hospitals. The point being that HCQ was intended to be widely distributed and used in the general public at the first sign of symptoms of the virus or as a preventative measure for the virus. It is ineffective and senseless to wait until the disease has progressed to such a degree that hospitalization is required. But Janet Woodcock and other co-conspirators sabotaged this plan.
On March 24, 2020, Dr. Janet Woodcock, FDA, directs Rick Bright to approve an Emergency Use Authorization for HCQ instead of an Investigational New Drug (IND) authorization. The effect was to limit the use of HCQ to hospitals. Screenshot is from Dr. Steven Hatfill's article.
On March 28, 2020, the FDA issued an Emergency Use Authorization for the use of Chloroquine and Hydroxychloroquine from the "National Strategic Stockpile." Later, after the Vanderbilt clinical trials, they revoked it. The revoke stamp over this .pdf was added at a later date.
On April 1, 2020, the PCORI’s Board awarded $50 million for clinical trials of HCQ under a "HERO" program. HERO is "Healthcare Worker Exposure Responding and Outcomes." Vanderbilt began ORCHID under this program somehow. ORCHID stands for "Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease."
About the PCORI: The PCORI is "Patient-Centered Outcomes Research Institute." From their website: "Members of PCORI’s Board of Governors, including its Chairperson and Vice Chairperson, are appointed by the Comptroller General of the United States. Under PCORI’s authorizing law, the Board includes the Directors of the National Institutes of Health and of the Agency for Healthcare Research and Quality, or their designees, at least 19 but no more than 21, representing a range of stakeholder audiences."
On April 2, 2020, Vanderbilt said that they enrolled the first patients in ORCHID. Vanderbilt University Medical Center: "The ORCHID trial ... funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health, enrolled its first patient on April 2 and will include hundreds of patients to determine if hydroxychloroquine is an effective treatment against the virus projected to hospitalize thousands of U.S. residents in the coming weeks."
The screenshot below is from a press release that was included in email correspondence included in the FOIA request of Judicial Watch. I still have some questions about the funding and origins of the ORCHID trials, but they were clearly associated with the NIH at Vanderbilt.
On April 4, 2020, Peter Navarro and Anthony Fauci argue in a meeting over the effectiveness of HCQ. Axios: "The White House coronavirus task force had its biggest fight yet on Saturday, pitting economic adviser Peter Navarro against infectious disease expert Anthony Fauci. ... Then Navarro got up. He brought over a stack of folders and dropped them on the table. People started passing them around. ... "And the first words out of his mouth are that the studies that he's seen, I believe they're mostly overseas, show 'clear therapeutic efficacy,'" said a source familiar with the conversation. "Those are the exact words out of his mouth." Fauci pushed back against Navarro, saying that there was only anecdotal evidence that hydroxychloroquine works against the coronavirus.
On April 5, 2020, Donald Trump said: "We've bought a tremendous amount of hydroxychloroquine."
On April 6, 2020, Katie Pavlich published "Thousands of Doctors: Yes, Hydroxychloroquine Works Against Wuhan Coronavirus" on Townhall. "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients. ... Dr. Mohammud Alam, an infectious disease specialist affiliated with Plainview Hospital, said 81 percent of infected covid patients he treated at three Long Island nursing homes recovered from the contagion. 'In this crisis, I realized I had to do something,' Alam said. ”I realized if this was my dad, what would I do? And I would do anything I could to help.” Alam said he decided he could not apply the touted combination of the antimalarial hydroxychloroquine and antibiotic azithromycin because the side effects could be potentially fatal for his high-risk patients, many of whom had underlying heart issues. So instead, Alam replaced azithromycin with another decades-old antibiotic that doesn’t pose any known risks to the heart. 'Every patient I've prescribed it to has been very, very ill and within 8 to 12 hours, they were basically symptom-free,' Cardillo told Eyewitness News. 'So clinically I am seeing a resolution.'" Note that Dr. Alam had an aversion to azithromycin that was being used in NIH clinical trials in ORCHID at Vanderbilt.
On April 24, 2020, FDA issued a Drug Safety Communication (DSC) cautioning against the use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of arrhythmias. The DSC described reports of serious cardiac events, including QT prolongation, in patients receiving hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines, for the prevention or treatment of COVID-19. FDA Review HCQ & Chloroquine. The FDA is cautioning against the same thing the NIH is testing, azithromycin, at this point.
On April 29, 2020, Anthony Fauci praised very weak results of a Remdesivir study. Anthony Fauci: "The data shows that Remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery. ... If you look at the time to recovery being shorter in the Remdesivir arm, it was 11 days compared to 15 days. ... Although a 31% improvement doesn't seem like a knock-out 100%, it is a very important proof of concept." CNN commented: "Normally, data about a drug's efficacy wouldn't be released this early from a preliminary trial. But 'whenever you have clear-cut evidence that a drug works, you have an ethical obligation to immediately let the people in the placebo group know so that they can have access,' Fauci said."
Let's break this down. Fauci praised a product that shortened "recovery" from 15 to 11 days against a placebo/ standard of care control group. This study didn't test Remdesivir against HCQ for time to recovery. Fauci's bias, and the bias of the studies the NIH funded, is transparent.
On April 29, 2020, Ralph Baric said that the results of the Remdesivir clinical trial was a "game changer." Note that UNC claimed they developed Remdesivir at the University of North Carolina. "Remdesivir was developed through an academic-corporate partnership between Gilead Sciences and the Baric Lab at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health." That's extremely misleading, and distracts from Vanderbilt's role in developing Remdesivir. This UNC press release distracts from Vanderbilt's financial and academic conflict of interest in testing HCQ in their ORCHID trials. More on this later. This screenshot is from UNC.edu.
On May 1, 2020, the FDA granted and Emergency Use Authorization for Remdesivir. FDA.gov EUA Remdesivir. "While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients."
On May 5, 2020, Susanna Naggie, MD, Duke Clinical Research Institute, announced to the PCORI’s Board of Governors that there was believed to be "an increased of cardiovascular events when used in combination with Azithromycin."
On June 15, 2020, the FDA revoked their Emergency Use Authorization for HCQ and chloroquine. fda.gov/media/138945. They said "Today’s request to revoke is based on new information, including clinical trial data results." Presumably this new information from the clinical trial data was from Vanderbilts' ORCHID study, which was shut down a few days later, based on some undisclosed "conditional power analysis." Among other things, the FDA said: "We now believe that the suggested dosing regimens for CQ and HCQ as detailed in the Fact Sheets are unlikely to produce an antiviral effect."
On June 19, 2020, the NHI stopped the ORCHID trial of HCQ at Vanderbilt. They said that this was "based on conditional power analysis." I have a lot of questions about this. First of all, I can't tell if the sample size of patients tested was 20, or 475, or some other number. When they say, "even if we enrolled twice the number of patients," it seems more likely in that context that they were discussing increasing the trial size from 20 to 40 patients, rather than 475 to 950, as increasing the scope in this quantity this would seemingly take another award. I cannot say though.
Second, I have to question what "conditions" were used in "conditional power analysis." I have questions about what the conditional power analysis even is. I believe that Vanderbilt should be forced to disclose all data so that their conclusions can be tested. Vanderbilt University should be subject to a FOIA to all records on this study. Anyway, they shut it down before the study was completed.
Judicial Watch FOIA request.pdf
On June 20, 2020, Anthony said he was not surprised at the decision to stop ORCHID. He said their recommendations (presumably against HCQ) could be made on "solid science" now. This is deceptive, designed-to-fail science, not solid science. Solid science would be to use Zinc with the HCQ and publish the results. This is sabotage to promote the NIH-developed Remdesivir, among other motives.
VANDERBILT'S ROLE IN DEVELOPMENT OF REMDESIVIR
There is no doubt that Ralph Baric was heavily involved in creating Remdesivir. It is best to think of Baric and UNC as a satellite of Vanderbilt and Mark Denison, in my opinion. Mark Denison and Ralph Baric are long-standing research partners. Denison's research precedes Baric's. Any way you want to look at it, Vanderbilt had a huge financial conflict of interest in conducting clinical trials of HCQ. This section is not meant to be a detailed discussion. Please read the underlying original source links to the universities of Vanderbilt and North Carolina if you would like to know more.
1990: Vanderbilt.edu: "The Denison Lab has been funded for more than 30 years (prior to 2020) by the National Institutes of Health to investigate the replication, pathogenesis and evolution of coronaviruses, including SARS, MERS and COVID-19.
1995. UNC.edu: “'A lot of my research pointed to the fact that new coronaviruses had the high potential to emerge and cause significant disease,' Baric says. He published a paper in 1995 suggesting that danger."
June 2003. UNC.edu: "this summer, the National Institutes of Health shoved money Baric’s way to support his efforts to produce the infectious SARS coronavirus clone. Within a few years, this clone could lead to an attenuated virus — a live SARS virus that has been tweaked so it’s no longer deadly. That, in turn, could be used to create an effective vaccine."
2007. Vanderbilt.edu: "...a seminal discovery by the Denison Lab in 2007 revealed that coronaviruses are the only RNA viruses that have proofreading enzymes that can “fix” mistakes it makes as it replicates. This discovery prompted Denison’s lab to look for drugs that could inhibit or bypass the coronavirus’s proofreading ability and slow down its replication. For six years they led the preclinical development of two such drugs, remdesivir and molnupiravir."
November 12, 2012: Vanderbilt University Medical Center: A collaborative study, published Nov. 11 in Nature Medicine, demonstrates a SARS-coronavirus, altered to lack the ability to “proofread” (correct mistakes in replication), begins to mutate much more rapidly and becomes unable to cause disease in mouse models. In effect, the alteration creates a profoundly weakened or attenuated SARS virus. ... The study is the culmination of more than a decade of collaboration between the laboratories of Mark Denison, M.D., Craig-Weaver Professor of Pediatrics and professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, and Ralph Baric, Ph.D., professor of Microbiology, Immunology and Epidemiology at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health. ... Denison’s lab developed the attenuated SARS virus by disabling a unique exoribonuclease (or ExoN) protein, referred to as a proofreading protein. Previous Vanderbilt studies had shown that disabling ExoN knocks out the virus’s ability to correct mistakes, increases mutations twentyfold, and stops its ability to cause disease, at least in the lab setting.
December 14, 2020: Vanderbilt.edu: Vanderbilt Chancellor Daniel Diermeier remarked: “The Denison Lab led the development of the COVID-19 antiviral remdesivir, which was for many months the only widely available and known treatment for COVID-19. He (Mark Denison) also was the first to show human antibody response to the Moderna vaccine,”
P.S. I attribute the term "Designed to Fail" to Dr. Zev Zelenko, who states: "There are classes of drugs called zinc ionophores. It turns out that one of them is hydroxychloroquine. There's also Ivermectin. There's also Quercetin. There's also EGCG. It doesn't matter to me which one you use, as long as you use a gun and a bullet. The bullet is zinc- kills the virus. But a bullet without a gun is useless. And a gun without a bullet is useless. So all those studies that use hydroxychloroquine without zinc were designed to fail."
Charles Wright
"We now believe that the suggested dosing regimens for CQ and HCQ as detailed in the Fact Sheets are unlikely to produce an antiviral effect." Very slick wordsmithing.
Vanderbilt put my Dad on vent and gave him remedevisir. He died April 2020.